Published in N Engl J Med on February 10, 2011
A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES) | NCT00496769
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2014) 3.36
Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol (2014) 2.94
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace (2015) 2.67
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J (2014) 2.32
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace (2015) 1.98
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69
Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ (2012) 1.68
Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ (2012) 1.61
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J (2014) 1.54
Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord (2015) 1.52
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J (2014) 1.50
Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace (2013) 1.40
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol (2013) 1.39
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Update on anti-coagulation in atrial fibrillation. QJM (2011) 1.28
Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis (2013) 1.20
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. Clin J Am Soc Nephrol (2016) 1.19
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.15
The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2011) 1.14
Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol (2012) 1.14
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs (2014) 1.13
Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. J Gen Intern Med (2015) 1.12
Health technology assessment and its role in the future development of the Indian healthcare sector. Perspect Clin Res (2012) 1.11
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract (2012) 1.07
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol (2013) 1.05
Managing atrial fibrillation in the global community: The European perspective. Glob Cardiol Sci Pract (2013) 1.04
New anticoagulants: A concise review. J Trauma Acute Care Surg (2012) 1.04
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J (2017) 0.95
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One (2013) 0.93
Anticoagulation in atrial fibrillation. BMJ (2014) 0.93
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J (2013) 0.92
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol (2015) 0.92
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ (2011) 0.90
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol (2013) 0.90
Atrial fibrillation in 2011: Stroke prevention in AF. Nat Rev Cardiol (2011) 0.90
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol (2014) 0.89
Impact of prescribed medications on patient safety in older people. Ther Adv Drug Saf (2012) 0.88
Long-term stroke prevention: We can do better. CMAJ (2017) 0.87
Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open (2014) 0.87
Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol (2015) 0.87
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
European research priorities for intracerebral haemorrhage. Cerebrovasc Dis (2011) 0.87
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. Int Arch Med (2013) 0.86
Practical management of patients on apixaban: a consensus guide. Thromb J (2013) 0.86
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol (2013) 0.86
The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary. Arrhythm Electrophysiol Rev (2013) 0.86
Atrial fibrillation in heart failure: what should we do? Eur Heart J (2015) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol (2011) 0.85
Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf (2014) 0.85
Prevention of cardioembolic stroke. Neurotherapeutics (2011) 0.85
Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. J Stroke (2016) 0.85
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth (2013) 0.84
Ophthalmic regional blocks: management, challenges, and solutions. Local Reg Anesth (2015) 0.84
Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation. Am Health Drug Benefits (2012) 0.84
[Management and therapy of atrial fibrillation in geriatric patients]. Z Gerontol Geriatr (2012) 0.84
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. J Am Heart Assoc (2016) 0.83
Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int J Gen Med (2013) 0.83
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83
Stroke prevention: managing modifiable risk factors. Stroke Res Treat (2012) 0.83
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One (2014) 0.82
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. Ther Clin Risk Manag (2015) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J (2011) 0.82
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. Korean Circ J (2015) 0.82
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol (2016) 0.81
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet (2015) 0.81
Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? J Am Heart Assoc (2015) 0.81
Associations between Cardioembolic Stroke and Obstructive Sleep Apnea. Sleep (2015) 0.81
Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81
A new paradigm shift in antithrombotic therapy. Front Pharmacol (2013) 0.81
Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management. Biomed Res Int (2015) 0.81
Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation. Curr Cardiol Rev (2012) 0.81
Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly. Circulation (2015) 0.81
How and When to Screen for Atrial Fibrillation after Stroke: Insights from Insertable Cardiac Monitoring Devices. J Stroke (2016) 0.81
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Genetics of gene expression and its effect on disease. Nature (2008) 21.35
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Mapping the genetic architecture of gene expression in human liver. PLoS Biol (2008) 19.44
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Variations in DNA elucidate molecular networks that cause disease. Nature (2008) 12.04
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Universal definition of myocardial infarction. Circulation (2007) 11.69
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet (2005) 11.40
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32